Mirna: the New Frontier in Cancer Medicine
Jingfang Ju,Jingting Jiang,Andrew Fesler
DOI: https://doi.org/10.4155/fmc.13.74
2013-01-01
Future Medicinal Chemistry
Abstract:Future Medicinal ChemistryVol. 5, No. 9 EditorialFree AccessmiRNA: the new frontier in cancer medicineJingfang Ju, Jingting Jiang & Andrew FeslerJingfang Ju* Author for correspondenceTranslational Research Laboratory, Department of Pathology, BST, L-9, Room 185, Stony Brook Medicine, Stony Brook University, Stony Brook, NY 11794, USA. , Jingting JiangDepartment of Tumor Biotherapy, The Third Affiliated Hospital of Soochow University, Changzhou, PR China & Andrew FeslerDepartment of Pathology, Stony Brook Medicine, Stony Brook University, Stony Brook, NY 11794, USAPublished Online:4 Jun 2013https://doi.org/10.4155/fmc.13.74AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit Keywords: cancer stem cellmicroRNAresistancetherapeuticsAlthough cancer is a genetic disease, epigenetic alternations (e.g., methylation, histone modification, noncoding RNA) are understood to play a key role in tumorigenesis. Such alterations enhance the ability of tumor cells to adopt to various growth conditions and to their unique tumor microenvironment.Approximately 2% of transcripts code for mRNA templates for protein synthesis, leaving a large percentage of noncoding RNAs (lncRNAs, miRNAs and piRNAs) many of which are highly conserved. The regulatory roles of these noncoding RNAs are just beginning to emerge. miRNAs are a class of small noncoding RNAs (e.g., siRNA, piRNA) with crucial regulatory function [1,2]. miRNAs modulate protein expression by promoting RNA degradation, inhibiting mRNA translation and, in some cases, affecting transcription. Although miRNA-mediated mRNA degradation occurs in mammals, most mammalian miRNAs are thought to repress target gene expression at the translational level via imperfect base pairing to the 3´-untranslated regions of their target mRNAs [1,3,4]. Such translational regulation provides the cell with a more precise, immediate and energy-efficient way of controlling the expression of protein as it induces rapid changes in protein synthesis [5], without excess transcriptional activation and subsequent steps in mRNA processing. In addition, translational control of gene expression has the advantage of being readily reversible, providing the cell with great flexibility in responding to various genotoxic and cytotoxic stresses. The relevance of miRNA in cancer was revealed a decade later when a link was found between miR-15, miR-16 and chronic lymphocytic leukemia [6]. The impact of miRNAs in cancer has become a new frontier in cancer research.In addition to the use miRNA mimics or anti-miRs as novel anti-cancer therapeutics alone, they have great potential to be used in combination with current chemotherapeutic compounds or radiation therapy. Resistance to chemotherapy and radiation therapy is one of the major reasons for the failure of clinical cancer management. Many factors contributed to the resistance mechanism and miRNAs have been shown to play major roles [7]. Post-transcriptional and translational controls mediated by miRNAs are crucial for tumors to develop resistance quickly by modulating protein synthesis in response to genotoxic stresses during anticancer chemotherapy and/or radiation therapy. As a result, modulating miRNA expression may offer new therapeutic strategies to overcome drug resistance in tumors. Chemotherapeutic agents (e.g., 5-fluorouracil) are ineffective in eliminating the slow proliferating cancer stem cells and, thus, novel approaches may help to overcome this issue. It is important to discover genes and pathways that are responsible for the resistance mechanism. Due to the broad influence of miRNA in gene expression, we believe that miRNAs may offer new insights into the resistance mechanism. In some cases, miRNAs may contribute to the development of resistance while in others they may help to overcome resistance. We have recently reported that miR-140 is overexpressed in CD133+HiCD44+Hi colon cancer stem-like cells and by reducing its expression, we can sensitize chemoresistant CD133+HiCD44+Hi colon cancer stem-like cells to 5-fluorouracil treatment [8].Tumor cells often lose their ability to undergo apoptosis due to defects in both intrinsic and extrinsic pathways. A number of miRNAs have been recently discovered to modulate key apoptosis protein targets (e.g., BCL-2, XIAP and SIRT-1). BCL-2 is an anti-apoptotic protein and is overexpressed in many cancer types. Several strands of miRNA have been reported to regulate BCL-2, increasing apoptosis. In gastric cancer cell lines high in BCL-2, miR-34 was observed to decrease BCL-2, increasing apoptosis and chemosensitivity [9]. Similar effects on apoptosis were found in primary chronic lymphocytic leukemia CLL cells with miR-181 targeting BCL-2 [10]. These are just some examples of how miRNA can engage in modulating apoptosis in cancer and have therapeutic potential.However, it is a difficult task to realize the dream of miRNA-based therapeutics and we are facing a number of challenges. Challenges, such as stability, toxicity, distribution and specificity to target tumor cells, are similar to those faced by other nucleic acid-based compounds. With the extensive efforts from both academia and industry, a number of solutions are now available to bring miRNA therapeutics closer to patients. With the issue of stability, extensive efforts have been made to modify miRNAs for enhanced stability by various modifications of nucleotides, such as 2´-O-methyl and 2´-O-methoxyethyl [11], anti-miRs, as well as with 3´-end-cholesterol conjugation [11,12] and locked nucleic acid [13–15]. Such modifications have been demonstrated to enhance anti-miR stability and affinity to miRNA. However, care has to be taken to avoid off-target effects due to extensive modifications.As for the in vivo delivery strategies, a number of approaches have been attempted such as the use of lentiviral vectors. Lentiviral vectors offer the advantage of stable gene therapy due to their integration into the genome. It has also been observed that lentiviral vectors offer greater transduction efficiency than other viral vectors in lung cancer [16]. However, there remains the concern that viral integration could disrupt the host genome, although some work has indicated that lentiviral integration poses a limited threat to genomic integrity. There is also concern regarding the development of an immune response to the lentiviral vector, which could limit the effectiveness of treatment. Other viral vectors for miRNA delivery are adenoviral-based vectors. Adenoviral-based vectors are episomal compared with lentiviral vectors but also have toxicity-related issues associated with immune response to the virus, as well as the concern of overcome existing immunity. Adeno-associated virus has also been reported to be effective at delivering miRNA in mouse models of liver cancer [17]. Nonviral delivery mechanisms have also demonstrated potential for therapeutic delivery of miRNA. These include liposomes, which have been shown to effectively deliver miRNA to cancer cells both locally and systemically in mouse xenograft models [13,18]. In addition, nanoparticles made of gold or synthetic polymers can effectively deliver miRNA when administered systemically in mouse xenograft models, leading to reduced tumor growth [19]. Recently an exosomal-based miRNA delivery has been reported with great potential as effective therapeutic delivery systems [20]. Exosomal delivery, offers a unique opportunity for miRNA delivery due to the fact that this system is naturally used in cellular communication, probably contributing to its stability in circulation. Exosomes can also be modified so that they can target delivery to a particular cell type. While exosome delivery seems promising, more work needs to be carried out, to make the production and isolation of exosomes an efficient process. There is also concern that an immune response could be mounted against exosomes unless they are harvested from immune-compatible cells.We are now in the middle of a critical and exciting time in miRNA-based cancer research and anticancer therapeutic development. In the next 5–10 years, the efforts from both academia and industry will pay off to realize the dream of having multitargeted miRNA-based anticancer therapy to benefit patients. miRNA-based diagnosis will also impact patient care by offering personalized diagnosis and tumor-tailored therapy. We remain optimistic about the miRNA-based diagnosis and future medicine in cancer.Financial & competing interests disclosureJ Ju is funded by the NIH. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.References1 Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell75(5),843–854 (1993).Crossref, Medline, CAS, Google Scholar2 Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans.Cell75(5),855–862 (1993).Crossref, Medline, CAS, Google Scholar3 Pillai RS, Bhattacharyya SN, Artus CG et al. Inhibition of translational initiation by Let-7 microRNA in human cells. Science309(5740),1573–1576 (2005).Crossref, Medline, CAS, Google Scholar4 Ruvkun G. Clarifications on miRNA and cancer. Science311(5757),36–37 (2006).Crossref, Medline, CAS, Google Scholar5 Dony C, Kessel M, Gruss P. Post-transcriptional control of myc and p53 expression during differentiation of the embryonal carcinoma cell line F9. Nature317(6038),636–639 (1985).Crossref, Medline, CAS, Google Scholar6 Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA99(24),15524–15529 (2002).Crossref, Medline, CAS, Google Scholar7 Yu F, Yao H, Zhu P et al. Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell131(6),1109–1123 (2007).Crossref, Medline, CAS, Google Scholar8 Song B, Wang Y, Xi Y et al. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene28(46),4065–4074 (2009).Crossref, Medline, CAS, Google Scholar9 Ji Q, Hao X, Meng Y et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer8,266 (2008).Crossref, Medline, Google Scholar10 Zhu DX, Zhu W, Fang C et al. miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis33(7),1294–1301 (2012).Crossref, Medline, CAS, Google Scholar11 Park JK, Kogure T, Nuovo GJ et al. miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res.71(24),7608–7616 (2011).Crossref, Medline, CAS, Google Scholar12 Krutzfeldt J, Rajewsky N, Braich R et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature438(7068),685–689 (2005).Crossref, Medline, Google Scholar13 Wiggins JF, Ruffino L, Kelnar K et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res.70(14),5923–5930 (2010).Crossref, Medline, CAS, Google Scholar14 Obad S, dos Santos CO, Petri A et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat. Genet.43(4),371–378 (2011).Crossref, Medline, CAS, Google Scholar15 Kurreck J, Wyszko E, Gillen C, Erdmann VA. Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res.30(9),1911–1918 (2002).Crossref, Medline, CAS, Google Scholar16 Chen C, Akerstrom V, Baus J, Lan MS, Breslin MB. Comparative analysis of the transduction efficiency of five adeno associated virus serotypes and VSV-G pseudotype lentiviral vector in lung cancer cells. Virol. J.10,86 (2013).Crossref, Medline, Google Scholar17 Kota J, Chivukula RR, O'Donnell KA et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell137(6),1005–1017 (2009).Crossref, Medline, CAS, Google Scholar18 Rai K, Takigawa N, Ito S et al. Liposomal delivery of microRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol. Cancer Ther.10(9),1720–1727 (2011).Crossref, Medline, CAS, Google Scholar19 Chen Y, Zhu X, Zhang X, Liu B, Huang L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol. Ther.18(9),1650–1656 (2010).Crossref, Medline, CAS, Google Scholar20 Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol.9(6),654–659 (2007).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited BymiR-223-5p Suppresses OTX1 to Mediate Malignant Progression of Lung Squamous Cell Carcinoma CellsComputational and Mathematical Methods in Medicine, Vol. 2021miR-223-5p Suppresses Tumor Growth and Metastasis in Non-Small Cell Lung Cancer by Targeting E2F8Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, Vol. 27, No. 2Development of novel miR-129 mimics with enhanced efficacy to eliminate chemoresistant colon cancer stem cells6 November 2017 | Oncotarget, Vol. 9, No. 10Reduced expression of miR-411 in intestinal type of gastric adenocarcinomaMeta Gene, Vol. 10Improving classification of mature microRNA by solving class imbalance problem16 May 2016 | Scientific Reports, Vol. 6, No. 1Activation of the miR-34a/SIRT1/p53 Signaling Pathway Contributes to the Progress of Liver Fibrosis via Inducing Apoptosis in Hepatocytes but Not in HSCs7 July 2016 | PLOS ONE, Vol. 11, No. 7microRNA, A Clinical Diagnostic and Prognostic Biomarker1 December 2019 | Annals of SBV, Vol. 5, No. 1The expanding regulatory universe of p53 in gastrointestinal cancer26 April 2016 | F1000Research, Vol. 5Steady-State Kinetics and Spectroscopic Characterization of Enzyme–tRNA Interactions for the Non-Heme Diiron tRNA-Monooxygenase, MiaE31 December 2014 | Biochemistry, Vol. 54, No. 2MicroRNAs as promising biomarkers in cancer diagnostics22 October 2014 | Biomarker Research, Vol. 2, No. 1Combating resistance: infectious diseasesBarry Gold17 July 2013 | Future Medicinal Chemistry, Vol. 5, No. 11Drug resistance: the problem that keeps on givingBarry Gold4 June 2013 | Future Medicinal Chemistry, Vol. 5, No. 9 Vol. 5, No. 9 Follow us on social media for the latest updates Metrics History Published online 4 June 2013 Published in print June 2013 Information© Future Science LtdKeywordscancer stem cellmicroRNAresistancetherapeuticsFinancial & competing interests disclosureJ Ju is funded by the NIH. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download
What problem does this paper attempt to address?
-
Exploiting the therapeutic potential of microRNAs in human cancer
William CS Cho
DOI: https://doi.org/10.1517/14728222.2012.663354
IF: 6.797
2012-02-18
Expert Opinion on Therapeutic Targets
Abstract:Dysregulation of microRNAs (miRNAs) has been widely shown to be associated with the development and progression of cancer. Recent studies discovered a handful of miRNAs with great potential to act as therapeutic targets in various human cancers. Inhibition or overexpression of these oncomirs may regulate the expressions of their associated genes, which in turn represses the proliferation or metastasis of different cancers. Some miRNAs can reverse the phenotype of epithelial-mesenchymal transition, while others can be utilized to sensitize cells to DNA-damaging drugs. Most of their anticancer abilities have been validated in preclinical animal models. A merit of miRNA-based therapy is that it can target plenty of genes in different signaling pathways, but this also comes with the drawback of many unknown off-target effects. In addition, successful delivery is also a major obstacle to effective miRNA-based therapeutics. Nevertheless, new findings from recent studies and the rapid advances in systemic drug delivery systems provide an optimistic perspective on the evolution of the field.
pharmacology & pharmacy
-
Trials and Tribulations of MicroRNA Therapeutics
Attila A. Seyhan
DOI: https://doi.org/10.3390/ijms25031469
IF: 5.6
2024-01-26
International Journal of Molecular Sciences
Abstract:The discovery of the link between microRNAs (miRNAs) and a myriad of human diseases, particularly various cancer types, has generated significant interest in exploring their potential as a novel class of drugs. This has led to substantial investments in interdisciplinary research fields such as biology, chemistry, and medical science for the development of miRNA-based therapies. Furthermore, the recent global success of SARS-CoV-2 mRNA vaccines against the COVID-19 pandemic has further revitalized interest in RNA-based immunotherapies, including miRNA-based approaches to cancer treatment. Consequently, RNA therapeutics have emerged as highly adaptable and modular options for cancer therapy. Moreover, advancements in RNA chemistry and delivery methods have been pivotal in shaping the landscape of RNA-based immunotherapy, including miRNA-based approaches. Consequently, the biotechnology and pharmaceutical industry has witnessed a resurgence of interest in incorporating RNA-based immunotherapies and miRNA therapeutics into their development programs. Despite substantial progress in preclinical research, the field of miRNA-based therapeutics remains in its early stages, with only a few progressing to clinical development, none reaching phase III clinical trials or being approved by the US Food and Drug Administration (FDA), and several facing termination due to toxicity issues. These setbacks highlight existing challenges that must be addressed for the broad clinical application of miRNA-based therapeutics. Key challenges include establishing miRNA sensitivity, specificity, and selectivity towards their intended targets, mitigating immunogenic reactions and off-target effects, developing enhanced methods for targeted delivery, and determining optimal dosing for therapeutic efficacy while minimizing side effects. Additionally, the limited understanding of the precise functions of miRNAs limits their clinical utilization. Moreover, for miRNAs to be viable for cancer treatment, they must be technically and economically feasible for the widespread adoption of RNA therapies. As a result, a thorough risk evaluation of miRNA therapeutics is crucial to minimize off-target effects, prevent overdosing, and address various other issues. Nevertheless, the therapeutic potential of miRNAs for various diseases is evident, and future investigations are essential to determine their applicability in clinical settings.
biochemistry & molecular biology,chemistry, multidisciplinary
-
RNA Cancer Nanomedicine: Nanotechnology-Mediated RNA Therapy.
Bijan Emiliano Ferdows,Dylan Neal Patel,Wei Chen,Xiangang Huang,Na Kong,Wei Tao
DOI: https://doi.org/10.1039/d1nr06991h
IF: 6.7
2022-01-01
Nanoscale
Abstract:It has been demonstrated that RNA molecules-mRNA, siRNA, microRNA, and sgRNA-regulate cancer-specific genes, and therefore, RNA-based therapeutics can suppress tumor progression and metastasis by selectively upregulating and silencing these genes. However, the innate defense mechanisms (e.g., exonucleases and RNases) involving the human immune system catalyze the degradation of exogenous RNAs. Thus, nonviral nanoparticles have been employed to deliver therapeutic RNAs for effective cancer gene therapy. In this minireview, we highlight efforts in the past decade to deliver therapeutic RNAs for cancer therapy using novel nanoparticles. Specifically, we review nanoparticles, including lipid, polymer, inorganic, and biomimetic materials, which have been employed to deliver therapeutic RNAs and evoke tumor suppressing responses. Finally, we discuss the challenges and considerations that may accelerate the clinical translation of nanotechnology-mediated RNA therapy.
-
A bionic "Trojan horse"-like gene delivery system hybridized with tumor and macrophage cell membrane for cancer therapy
Tianli Shen,Shuanying Yang,Xiaoyan Qu,Zilu Chen,Lizhong Zeng,Xuejun Sun,Yuyao Lin,Meng Luo,Bo Lei,Chenyang Yue,Chunhong Ma,Nan Hu,Wei Wang,Long Zhang
DOI: https://doi.org/10.1016/j.jconrel.2023.04.046
IF: 11.467
2023-05-06
Journal of Controlled Release
Abstract:MiRNA-based gene therapy as a novel targeted therapy has yielded promising results in experimental cancer treatment, however, the inefficient delivery of miRNA to target tissues has limited its application in vivo . Here a unique dual-membrane-camouflaged miRNA21 antagomir delivery nanoplatform (/miR21) with immune escape and homologous targeting properties was constructed by cancer cell membrane and macrophage membrane. Different from the single-cell membrane camouflage strategy, the dual-membrane camouflage miRNA21 antagomir delivery nanoplatform based on modification of CD47 protein with immune escape signal and galectin-3 protein with tumor cell aggregation enables efficient, safe and targeted therapy for colon cancer and lung metastases. Camouflaged with the dual-cell membrane, the "Trojan horse" like "pseudo-tumor cell" and/or "pseudo-macrophage" (/miR21) carried the target gene miR21 antagomir to the tumor site and showed significant anti-tumor properties at the periphery and the core of subcutaneous tumor tissues. In addition, /miR21 was more likely to penetrate dense tumor tissues and function within the tumor mass than NPs/miR21 without membrane coating. /miR21 can deliver miR21 antagomir into MC38 cancer cells and tumor tissues, promote tumor apoptosis, and regulate the expression of Bcl2 and Ki67. Moreover, the /miR21 gene delivery system not only can effectively inhibit the progression of subcutaneous tumors and lung metastases, but also showed minimal toxicity and good biosafety, making this delivery system particularly attractive for future translational research.
pharmacology & pharmacy,chemistry, multidisciplinary
-
Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: New trends in the development of miRNA therapeutic strategies in oncology (Review)
ROBERTO GAMBARI,ELEONORA BROGNARA,DEMETRIOS A. SPANDIDOS,ENRICA FABBRI
DOI: https://doi.org/10.3892/ijo.2016.3503
2016-05-04
International Journal of Oncology
Abstract:MicroRNA (miRNA or miR) therapeutics in cancer are based on targeting or mimicking miRNAs involved in cancer onset, progression, angiogenesis, epithelial-mesenchymal transition and metastasis. Several studies conclusively have demonstrated that miRNAs are deeply involved in tumor onset and progression, either behaving as tumor-promoting miRNAs (oncomiRNAs and metastamiRNAs) or as tumor suppressor miRNAs. This review focuses on the most promising examples potentially leading to the development of anticancer, miRNA-based therapeutic protocols. The inhibition of miRNA activity can be readily achieved by the use of miRNA inhibitors and oligomers, including RNA, DNA and DNA analogues (miRNA antisense therapy), small molecule inhibitors, miRNA sponges or through miRNA masking. On the contrary, the enhancement of miRNA function (miRNA replacement therapy) can be achieved by the use of modified miRNA mimetics, such as plasmid or lentiviral vectors carrying miRNA sequences. Combination strategies have been recently developed based on the observation that i) the combined administration of different antagomiR molecules induces greater antitumor effects and ii) some anti-miR molecules can sensitize drug-resistant tumor cell lines to therapeutic drugs. In this review, we discuss two additional issues: i) the combination of miRNA replacement therapy with drug administration and ii) the combination of antagomiR and miRNA replacement therapy. One of the solid results emerging from different independent studies is that miRNA replacement therapy can enhance the antitumor effects of the antitumor drugs. The second important conclusion of the reviewed studies is that the combination of anti-miRNA and miRNA replacement strategies may lead to excellent results, in terms of antitumor effects.
-
Therapeutic Delivery of Tumor Suppressor miRNAs for Breast Cancer Treatment
Sonali S. Shinde,Sakeel Ahmed,Jonaid Ahmad Malik,Umme Hani,Afreen Khanam,Faisal Ashraf Bhat,Suhail Ahmad Mir,Mohammed Ghazwani,Shadma Wahab,Nazima Haider,Abdulrahman A. Almehizia
DOI: https://doi.org/10.3390/biology12030467
2023-03-20
Biology
Abstract:The death rate from breast cancer (BC) has dropped due to early detection and sophisticated therapeutic options, yet drug resistance and relapse remain barriers to effective, systematic treatment. Multiple mechanisms underlying miRNAs appear crucial in practically every aspect of cancer progression, including carcinogenesis, metastasis, and drug resistance, as evidenced by the elucidation of drug resistance. Non-coding RNAs called microRNAs (miRNAs) attach to complementary messenger RNAs and degrade them to inhibit the expression and translation to proteins. Evidence suggests that miRNAs play a vital role in developing numerous diseases, including cancer. They affect genes critical for cellular differentiation, proliferation, apoptosis, and metabolism. Recently studies have demonstrated that miRNAs serve as valuable biomarkers for BC. The contrast in the expression of miRNAs in normal tissue cells and tumors suggest that miRNAs are involved in breast cancer. The important aspect behind cancer etiology is the deregulation of miRNAs that can specifically influence cellular physiology. The main objective of this review is to emphasize the role and therapeutic capacity of tumor suppressor miRNAs in BC and the advancement in the delivery system that can deliver miRNAs specifically to cancerous cells. Various approaches are used to deliver these miRNAs to the cancer cells with the help of carrier molecules, like nanoparticles, poly D, L-lactic-co-glycolic acid (PLGA) particles, PEI polymers, modified extracellular vesicles, dendrimers, and liposomes. Additionally, we discuss advanced strategies of TS miRNA delivery techniques such as viral delivery, self-assembled RNA-triple-helix hydrogel drug delivery systems, and hyaluronic acid/protamine sulfate inter-polyelectrolyte complexes. Subsequently, we discuss challenges and prospects on TS miRNA therapeutic delivery in BC management so that miRNAs will become a routine technique in developing individualized patient profiles.
biology
-
Micelle-like nanoparticles as siRNA and miRNA carriers for cancer therapy
Daniel F. Costa,Vladimir P. Torchilin
DOI: https://doi.org/10.1007/s10544-018-0298-0
2018-07-12
Biomedical Microdevices
Abstract:Gene therapy has emerged as an alternative in the treatment of cancer, particularly in cases of resistance to chemo and radiotherapy. Different approaches to deliver genetic material to tumor tissues have been proposed, including the use of small non-coding RNAs due to their multiple mechanisms of action. However, such promise has shown limits in in vivo application related to RNA’s biological instability and stimulation of immunity, urging the development of systems able to overcome those barriers. In this review, we discuss the use of RNA interference in cancer therapy with special attention to the role of siRNA and miRNA and to the challenges of their delivery in vivo. We introduce a promising class of drug delivery system known as micelle-like nanoparticles and explore their synthesis and advantages for gene therapy as well as the recent findings in in vitro, in vivo and clinical studies.
engineering, biomedical,nanoscience & nanotechnology
-
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rajesha Rupaimoole,Frank J. Slack
DOI: https://doi.org/10.1038/nrd.2016.246
IF: 112.288
2017-02-17
Nature Reviews Drug Discovery
Abstract:Key PointsMicroRNAs (miRNAs) belong to class of small non-coding RNAs that are involved in development and diseases. miRNAs control gene expression by targeting mRNAs based on sequence complementarity.miRNAs can serve as oncomiRs by targeting tumour suppressor mRNAs and as tumour suppressor miRNAs by targeting mRNAs that encode oncoproteins.The deregulation of miRNAs in disease conditions can be harnessed as potential therapeutics by either miRNA replacement therapy using miRNA mimics or inhibition of miRNA function by antimiRs.Two of the major focus areas in the development of miRNA therapeutics are enhancing the in vivo stability of therapeutic RNA molecules and designing optimal delivery systems for disease-specific release with minimal toxicity.Numerous preclinical studies utilizing various disease models have tested the use of these new-generation therapeutics, and several miRNA-based therapeutics have advanced into clinical testing.
pharmacology & pharmacy,biotechnology & applied microbiology
-
NiFe-layered double hydroxide nanoparticle for co-delivery of DOX and siRNA to overcome multidrug resistance in MCF-7/ADR cells
Yan-Ni Bao,Xiu-Li Xie,Li-Li Lu,Wen-Hao Liu,Yu-Chen Ma,Yi-Jun Ke,Huan Ren,Li-Na Tan,Li-Fang Wu,Jue Song,Yong Jin,Xiao-Yan Liu
DOI: https://doi.org/10.1016/j.jddst.2023.104829
IF: 5
2023-08-09
Journal of Drug Delivery Science and Technology
Abstract:Multidrug resistance (MDR) continues to be the major limiting factor in the cure of patients with cancer. Studies have shown that tumor multidrug resistance may be closely related to the multidrug-resistant protein secreted by itself, such as breast cancer resistance protein (BCRP). Therefore, inhibiting the production of multidrug-resistant proteins through genetic intervention may reverse tumor drug resistance. Herein, we use layered double hydroxide nanoparticles (LDH) to co-deliver DOX and siRNA targeting BCRP RNA to reverse the resistance of MCF-7/ADR cells and enhance the anticancer activity of doxorubicin (DOX). In this platform, DOX is encapsulated in the nanoparticles, which have the characteristics of high drug loading and strong controlled-release, and siRNA is tightly adsorbed on the surface of the nanoparticles through electrostatic action to avoid the degradation of siRNA. Moreover, NiFe-LDH shows excellent ability to deliver siRNA and DOX into cells and enhance the internalization of siRNA and DOX. The experiment further confirms that (1:1) shows an effective gene silencing effect and down-regulated the expression of BCRP. In vitro experiments show that inhibits cell proliferation by affecting the cell cycle and inducing apoptosis. In vivo experiments, MCF-7/ADR xenotransplantation therapy also reveals that has a significant antitumor effect. We believe that this work has great potential for reversing the drug resistance of breast cancer and improving the effectiveness of chemotherapy. Graphical abstract Download : Download high-res image (378KB) Download : Download full-size image According to International Association for the Study of Pain (IASP), the definition of pain is "an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage." Pain aids as a protective role in the alertness of a person in case of tissue injury as well as threats to bodily integrity and survival. Moreover, deprivation of the existence of pain as a priority health condition from so many years has caused less understanding of the mechanism and pain management as well as affecting the development along with the execution of advanced therapies. Nowadays, progress is underway to modulate the classical view of pain and aiming for its recognition as a genuine health problem or better as a unique medical disease rather than a symptom of a disease. Nanomedicine-based technologies can also become useful in the diagnosis of the disease. For the repairing or healing of the damaged nerve tissue, spinal cord injuries and other types of injuries like bone and cartilage which are related to extreme pain, advancements in tissue engineering are very useful. There are various types of nanomedicines either increase the advantages or decrease the limitations of the present formulations. This reviewed chapter highlights the types of pain, the mechanism behind pain perception, and outbreak research prevailing in nanomedicine for management of pain in patients. Drug loading is a key procedure in the preparation of drug-loaded nano-carriers. In this study, the paclitaxel (PTX)-loaded polymeric complex micelles (FA-P123-PTX/PTX micelles) with double drug-loading strategies were designed and prepared to improve the drug loading percentage of carriers and its anti-tumor efficiency. PTX was simultaneously conjugated to pluronic P123 (P123) polymer and encapsulated inside the P123 complex micelle. Folate (FA) was linked to the surface of micelles for the active target delivery of micelles to tumor cells. The FA-P123-PTX/PTX micelles showed spherical shaped with high drug loading of 18.08 ± 0.64%. The results of cellular uptake studies suggested that FA could promote the internalization of micelles into the FR positive cells. FA-P123-PTX/PTX micelles showed significant higher anti-tumor activity against FR positive tumor cells compared to Taxol ® ( p < 0.05). Moreover, the FA-P123-PTX/PTX micelles exhibited higher anti-tumor efficacy in B16 bearing mice with better safety property compared with Taxol ® . These results suggested that FA-P123-PTX/PTX micelles with double drug-loading strategies showed great potential for targeted delivery of anti-cancer drugs. Melanoma is a highly invasive malignant skin tumor having high metastatic rate and poor prognosis. The biology of melanoma is controled by miRNAs. The miRNA-183 cluster, which is composed of miRNA-183∼96∼182 genes, plays an important roles in tumor development. In order to investigate the role and action -Abstract Truncated-
pharmacology & pharmacy
-
miRNA: A Promising Therapeutic Target in Cancer
R. Naidu,C. Poh,Noraini Abd-Aziz,Kanwal Khalid,Amrutha Menon
DOI: https://doi.org/10.3390/ijms231911502
IF: 5.6
2022-09-29
International Journal of Molecular Sciences
Abstract:microRNAs are small non-coding RNAs that regulate several genes post-transcriptionally by complementarity pairing. Since discovery, they have been reported to be involved in a variety of biological functions and pathologies including cancer. In cancer, they can act as a tumor suppressor or oncomiR depending on the cell type. Studies have shown that miRNA-based therapy, either by inhibiting an oncomiR or by inducing a tumor suppressor, is effective in cancer treatment. This review focusses on the role of miRNA in cancer, therapeutic approaches with miRNAs and how they can be effectively delivered into a system. We have also summarized the patents and clinical trials in progress for miRNA therapy.
Medicine,Biology
-
Encapsulation of miRNA and siRNA into Nanomaterials for Cancer Therapeutics
Mina Zare,Rakesh Pemmada,Maya Madhavan,Aswathy Shailaja,Seeram Ramakrishna,Sumodan Padikkala Kandiyil,James M. Donahue,Vinoy Thomas
DOI: https://doi.org/10.3390/pharmaceutics14081620
IF: 6.525
2022-08-04
Pharmaceutics
Abstract:Globally, cancer is amongst the most deadly diseases due to the low efficiency of the conventional and obsolete chemotherapeutic methodologies and their many downsides. The poor aqueous solubility of most anticancer medications and their low biocompatibility make them ineligible candidates for the design of delivery systems. A significant drawback associated with chemotherapy is that there are no advanced solutions to multidrug resistance, which poses a major obstacle in cancer management. Since RNA interference (RNAi) can repress the expression of genes, it is viewed as a novel tool for advanced drug delivery. this is being explored as a promising drug targeting strategy for the treatment of multiple diseases, including cancer. However, there are many obstructions that hinder the clinical uses of siRNA drugs due to their low permeation into cells, off-target impacts, and possible unwanted immune responses under physiological circumstances. Thus, in this article, we review the design measures for siRNA conveyance frameworks and potential siRNA and miRNA drug delivery systems for malignant growth treatment, including the use of liposomes, dendrimers, and micelle-based nanovectors and functional polymer–drug delivery systems. This article sums up the advancements and challenges in the use of nanocarriers for siRNA delivery and remarkably centers around the most critical modification strategies for nanocarriers to build multifunctional siRNA and miRNA delivery vectors. In short, we hope this review will throw light on the dark areas of RNA interference, which will further open novel research arenas in the development of RNAi drugs for cancer.
pharmacology & pharmacy
-
Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer
Gaofeng Liang,Yanliang Zhu,Doulathunnisa Jaffar Ali,Tian Tian,Huantian Xu,Ke Si,Bo Sun,Baoan Chen,Zhongdang Xiao
DOI: https://doi.org/10.1186/s12951-019-0563-2
IF: 10.2
2020-01-09
Journal of Nanobiotechnology
Abstract:Abstract Background 5-Fluorouracil (5-FU) has been commonly prescribed for patients with colorectal cancer (CRC), but resistance to 5-FU is one of the main reasons for failure in CRC. Recently, microRNAs (miRNAs) have been established as a means of reversing the dilemma by regulating signaling pathways involved in initiation and progression of CRC. However, how to safely and effectively deliver miRNA to target cells becomes a main challenge. Results In this study, Engineered exosomes were exploited to simultaneously deliver an anticancer drug 5-FU and miR-21 inhibitor oligonucleotide (miR-21i) to Her2 expressing cancer cells. Purified engineered exosomes from the donor cells loaded with 5-FU and miR-21i via electroporation to introduce into 5-FU-resistant colorectal cancer cell line HCT-116 5FR . Furthermore, systematic administration of 5-FU and miR-21i loaded exosomes in tumor bearing mice indicated a significantly anti-tumor effect. The results showed that the engineered exosome-based 5-FU and miR-21i co-delivery system could efficiently facilitate cellular uptake and significantly down-regulate miR-21 expression in 5-FU resistant HCT-116 5FR cell lines. Consequently, the down-regulation of miR-21 induced cell cycle arrest, reduced tumor proliferation, increased apoptosis and rescued PTEN and hMSH2 expressions, regulatory targets of miR-21. Of particular importance was the significant reduction in tumor growth in a mouse model of colon cancer with systematic administration of the targeting miR-21i. More excitedly, the combinational delivery of miR-21i and 5-FU with the engineered exosomes effectively reverse drug resistance and significantly enhanced the cytotoxicity in 5-FU-resistant colon cancer cells, compared with the single treatment with either miR-21i or 5-FU. Conclusion The strategy for co-delivering the functional small RNA and anticancer drug by exosomes foreshadows a potential approach to reverse the drug resistance in CRC and thus to enhance the efficacy of the cancer treatment.
biotechnology & applied microbiology,nanoscience & nanotechnology
-
Advances in the discovery of microRNA-based anticancer therapeutics: latest tools and developments
Kenneth K.W. To,Winnie Fong,Christy W.S. Tong,Mingxia Wu,Wei Yan,William C.S. Cho
DOI: https://doi.org/10.1080/17460441.2020.1690449
2019-11-19
Expert Opinion on Drug Discovery
Abstract:<span><b>Introduction</b>: MicroRNAs (miRNAs) are small endogenous non-coding RNAs that repress the expression of their target genes by reducing mRNA stability and/or inhibiting translation. miRNAs are known to be aberrantly regulated in cancers. Modulators of miRNA (mimics and antagonists) have emerged as novel therapeutic tools for cancer treatment.<b>Areas covered</b>: This review summarizes the various strategies that have been applied to correct the dysregulated miRNA in cancer cells. The authors also discuss the recent advances in the technical development and preclinical/clinical evaluation of miRNA-based therapeutic agents.<b>Expert opinion</b>: Application of miRNA-based therapeutics for cancer treatment is appealing because they are able to modulate multiple dysregulated genes and/or signaling pathways in cancer cells. Major obstacles hindering their clinical development include drug delivery, off-target effects, efficacious dose determination, and safety. Tumor site-specific delivery of novel miRNA therapeutics may help to minimize off-target effects and toxicity. Combination of miRNA therapeutics with other anticancer treatment modalities could provide a synergistic effect, thus allowing the use of lower dose, minimizing off-target effects, and improving the overall safety profile in cancer patients. It is critical to identify individual miRNAs with cancer type-specific and context-specific regulation of oncogenes and tumor-suppressor genes in order to facilitate the precise use of miRNA anticancer therapeutics.</span>
pharmacology & pharmacy
-
Nanostructured lipid carriers for MicroRNA delivery in tumor gene therapy
Hairong Wang,Shiming Liu,Li Jia,Fengyun Chu,Ya Zhou,Zhixu He,Mengmeng Guo,Chao Chen,Lin Xu
DOI: https://doi.org/10.1186/s12935-018-0596-x
IF: 6.429
2018-07-13
Cancer Cell International
Abstract:MicroRNAs (miRNAs), which are endogenous about 20–23 nucleotides non-coding RNAs, have been acted as post-transcriptional regulators of gene expression. Current studies demonstrated that miRNAs are promising candidates for tumor gene therapy because of their important biological functions in tumor cell proliferation, metastasis, apoptosis, and drug resistance. As an important delivery system, nanostructured lipid carriers (NLCs) have great potential in tumor gene therapy, particularly for miRNA delivery, due to low toxicity, low immunogenicity, long metabolic cycles, and easy modification. This article reviews recent research progress on NLCs for miRNA delivery in tumor gene therapy and prospective applications.
oncology
-
Mesenchymal stem cell (MSC)-derived exosomes as novel vehicles for delivery of miRNAs in cancer therapy
Behnoush Sohrabi,Behnaz Dayeri,Elahe Zahedi,Shahrouz Khoshbakht,Najme Nezamabadi Pour,Hamta Ranjbar,Abolfazl Davari Nejad,Mahdi Noureddini,Behrang Alani
DOI: https://doi.org/10.1038/s41417-022-00427-8
IF: 5.854
2022-01-26
Cancer Gene Therapy
Abstract:Mesenchymal stem cells (MSCs) are known as promising sources for cancer therapy and can be utilized as vehicles in cancer gene therapy. MSC-derived exosomes are central mediators in the therapeutic functions of MSCs, known as the novel cell-free alternatives to MSC-based cell therapy. MSC-derived exosomes show advantages including higher safety as well as more stability and convenience for storage, transport and administration compared to MSCs transplant therapy. Unmodified MSC-derived exosomes can promote or inhibit tumors while modified MSC-derived exosomes are involved in the suppression of cancer development and progression via the delivery of several therapeutics molecules including chemotherapeutic drugs, miRNAs, anti-miRNAs, specific siRNAs, and suicide gene mRNAs. In most malignancies, dysregulation of miRNAs not only occurs as a consequence of cancer progression but also is directly involved during tumor initiation and development due to their roles as oncogenes (oncomiRs) or tumor suppressors (TS-miRNAs). MiRNA restoration is usually achieved by overexpression of TS-miRNAs using synthetic miRNA mimics and viral vectors or even downregulation of oncomiRs using anti-miRNAs. Similar to other therapeutic molecules, the efficacy of miRNAs restoration in cancer therapy depends on the effectiveness of the delivery system. In the present review, we first provided an overview of the properties and potentials of MSCs in cancer therapy as well as the application of MSC-derived exosomes in cancer therapy. Finally, we specifically focused on harnessing the MSC-derived exosomes for the aim of miRNA delivery in cancer therapy.
oncology,genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology
-
Novel approaches in cancer treatment: preclinical and clinical development of small non-coding RNA therapeutics
Rossana Cuciniello,Stefania Filosa,Stefania Crispi
DOI: https://doi.org/10.1186/s13046-021-02193-1
2021-12-01
Abstract:Abstract Short or small interfering RNAs (siRNAs) and microRNA (miRNAs) are molecules similar in size and function able to inhibit gene expression based on their complementarity with mRNA sequences, inducing the degradation of the transcript or the inhibition of their translation. siRNAs bind specifically to a single gene location by sequence complementarity and regulate gene expression by specifically targeting transcription units via posttranscriptional gene silencing. miRNAs can regulate the expression of different gene targets through their imperfect base pairing. This process - known as RNA interference (RNAi) - modulates transcription in order to maintain a correct physiological environment, playing a role in almost the totality of the cellular pathways. siRNAs have been evolutionary evolved for the protection of genome integrity in response to exogenous and invasive nucleic acids such as transgenes or transposons. Artificial siRNAs are widely used in molecular biology for transient silencing of genes of interest. This strategy allows to inhibit the expression of any target protein of known sequence and is currently used for the treatment of different human diseases including cancer. Modifications and rearrangements in gene regions encoding for miRNAs have been found in cancer cells, and specific miRNA expression profiles characterize the developmental lineage and the differentiation state of the tumor. miRNAs with different expression patterns in tumors have been reported as oncogenes (oncomirs) or tumor-suppressors (anti-oncomirs). RNA modulation has become important in cancer research not only for development of early and easy diagnosis tools but also as a promising novel therapeutic approach. Despite the emerging discoveries supporting the role of miRNAs in carcinogenesis and their and siRNAs possible use in therapy, a series of concerns regarding their development, delivery and side effects have arisen. In this review we report the biology of miRNAs and siRNAs in relation to cancer summarizing the recent methods described to use them as novel therapeutic drugs and methods to specifically deliver them to cancer cells and overcome the limitations in the use of these molecules.
oncology
-
The Role of miRNA in Tumor Immune Escape and miRNA-Based Therapeutic Strategies
Zhengjia Zhang,Qingcai Huang,Liuchunyang Yu,Dongjie Zhu,Yang Li,Zeyu Xue,Zhenglai Hua,Xinyi Luo,Zhiqian Song,Cheng Lu,Ting Zhao,Yuanyan Liu
DOI: https://doi.org/10.3389/fimmu.2021.807895
IF: 7.3
2022-01-18
Frontiers in Immunology
Abstract:Tumor immune escape is a critical step in the malignant progression of tumors and one of the major barriers to immunotherapy, making immunotherapy the most promising therapeutic approach against tumors today. Tumor cells evade immune surveillance by altering the structure of their own, or by causing abnormal gene and protein expression, allowing for unrestricted development and invasion. These genetic or epigenetic changes have been linked to microRNAs (miRNAs), which are important determinants of post-transcriptional regulation. Tumor cells perform tumor immune escape by abnormally expressing related miRNAs, which reduce the killing effect of immune cells, disrupt the immune response, and disrupt apoptotic pathways. Consequently, there is a strong trend toward thoroughly investigating the role of miRNAs in tumor immune escape and utilizing them in tumor treatment. However, because of the properties of miRNAs, there is an urgent need for a safe, targeted and easily crossed biofilm vehicle to protect and deliver them in vivo , and exosomes, with their excellent biological properties, have successfully beaten traditional vehicles to provide strong support for miRNA therapy. This review summarizes the multiple roles of miRNAs in tumor immune escape and discusses their potential applications as an anti-tumor therapy. Also, this work proposes exosomes as a new opportunity for miRNA therapy, to provide novel ideas for the development of more effective tumor-fighting therapeutic approaches based on miRNAs.
immunology
-
Potential Microrna Targets For Cancer Chemotherapy
Subee Tan,Yihan Wu,Chen-Yu Zhang,Jinbo Li
DOI: https://doi.org/10.2174/0929867311320290003
IF: 4.74
2013-01-01
Current Medicinal Chemistry
Abstract:MicroRNA (miRNA) is an important type of non-coding RNAs with both physiological and pathological functions in human beings. Aberrant expression of miRNAs has been found in tumor tissues and the expression profile of certain groups of miRNAs is now emerging as bio-marker for cancer. It has been confirmed that miRNAs can exert oncogenic or tumor-suppressive functions through repressing the expression of their target genes which play different roles in tumorigenesis. The identification of oncogenic or tumor-suppressive miRNAs allows potential applications of these miRNAs as targets for cancer chemotherapy. In this review, we summarized the well-known cancer-related miRNAs reported in recent years and the roles they played in tumorigenesis and progression by targeting specific genes. Strategies developed to modulate the function or expression of the dysregulated miRNAs are also reviewed with recent examples illustrating their potential applications in cancer chemotherapy.
-
RNAi treatment has been shown to successfully modify human-related target gene expression, including cancer. It has the capacity to control non-standard oncogenes, such as oncogenic lncRNAs
Moataz Dowaidar
DOI: https://doi.org/10.31219/osf.io/bwqep
2021-06-10
Abstract:Recent breakthroughs in clinical research and deployment of RNAi therapeutics have validated siRNA's promise to cure human diseases. RNAi therapy has been proven to effectively alter the expression of human-related target genes, including cancer. It has the potential to regulate oncogenes not addressed by standard treatment, such as oncogenic lncRNAs, to treat cancer more successfully. Due to their intrinsic liver affinity, successful RNAi therapies in clinical development primarily target liver diseases. Systemic dispersion of therapeutic siRNAs is an effective cancer therapy technique, especially for advanced diseases. Despite recent advances in siRNA delivery technologies, a problem remains with efficiently distributing siRNAs into solid tumors and cancer cells. To overcome several challenges to the dispersion of siRNA in cancer cells' cytoplasm, novel and highly effective delivery systems need to be devised. Delivery devices' ability to sense and adjust to environmental changes throughout the delivery process can make cytosolic distribution into cancer cells more efficient and accurate. Due to their well-defined and simple chemical structures and their multifunctionalities to respond to environmental changes to facilitate efficient cytosolic transport, environment-responsive lipids are promising platforms for clinical development to deliver siRNA. The primary benefit of simple, well-defined lipid structures over complex systems for cost-effective CMC and clinical translation is the simple, well-defined lipid structures. Environment-responsive lipids might be considered as simple, clever siRNA delivery methods that can overcome delivery difficulties for successful cancer treatment.
-
Revolutionizing cancer therapy: nanoformulation of miRNA-34 – enhancing delivery and efficacy for various cancer immunotherapies: a review
Marola Paula Fawzy,Hatem A. F. M. Hassan,Nada K. Sedky,Mohamed S. Nafie,Rana A. Youness,Sherif Ashraf Fahmy
DOI: https://doi.org/10.1039/d4na00488d
IF: 5.598
2024-09-23
Nanoscale Advances
Abstract:Despite recent advancements in cancer therapies, challenges such as severe toxic effects, non-selective targeting, resistance to chemotherapy and radiotherapy, and recurrence of metastatic tumors persist. Consequently, there has been considerable effort to explore innovative anticancer compounds, particularly in immunotherapy, which offer the potential for enhanced biosafety and efficacy in cancer prevention and treatment. One such avenue of exploration involves the miRNA-34 (miR-34) family, known for its ability to inhibit tumorigenesis across various cancers. Dysregulation of miR-34 has been observed in several human cancers, and it is recognized as a tumor suppressor microRNA due to its synergistic interaction with the well-established tumor suppressor p53. However, challenges have arisen with the therapeutic application of miR-34a. These include its susceptibility to degradation by RNase in serum, limiting its ability to penetrate capillary endothelium and reach target cells, as well as reports of immunoreactive adverse reactions. Furthermore, unexpected side effects may occur, such as the accumulation of therapeutic miRNAs in healthy tissues due to interactions with serum proteins on nano-vector surfaces, nanoparticle breakdown in the bloodstream due to shearing stress, and unsuccessful extravasation of nanocarriers to target cells owing to interstitial fluid pressure. Despite these challenges, miR-34a remains a promising candidate for cancer therapy, and other members of the miR-34 family have also shown potential in inhibiting tumor cell proliferation. While the in vivo applications of miR-34b/c are limited, they warrant further exploration for oncotherapy. Recently, procedures utilizing nanoparticles have been developed to address the challenges associated with the clinical use of miR-34, demonstrating efficacy both in vitro and in vivo . This review highlights emerging trends in nanodelivery systems for miR-34 targeting cancer cells, offering insights into novel nanoformulations designed to enhance the anticancer therapeutic activity and targeting precision of miR-34. As far as current knowledge extends, no similar recent review comprehensively addresses the diverse nanoformulations aimed at optimizing the therapeutic potential of miR-34 in anticancer strategies.
materials science, multidisciplinary,nanoscience & nanotechnology,chemistry